Medication management has evolved from intuition-based treatments to population health, which emerged in the mid-1990s with a top-down, rules-based approach that treats individuals as hypotheticals, says Colin Hill, chairman and CEO of GNS Healthcare.
But traditional methods to determine which patients to reach out to don’t target people who are at high risk of negative health consequences. For example, OmedaRx might now determine that 5,000 people need intervention. With big data and more advanced analytics, it’s possible to determine that only 700 are really at risk.
Read the full article here.